176 related articles for article (PubMed ID: 32372382)
1. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
Patel S; Hickman A; Frederich R; Johnson S; Huyck S; Mancuso JP; Gantz I; Terra SG
Diabetes Ther; 2020 Jun; 11(6):1347-1367. PubMed ID: 32372382
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.
Liu J; Tarasenko L; Pong A; Huyck S; Wu L; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
Curr Med Res Opin; 2020 Aug; 36(8):1277-1284. PubMed ID: 32324082
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Liu J; Patel S; Cater NB; Wu L; Huyck S; Terra SG; Hickman A; Darekar A; Pong A; Gantz I
Diabetes Obes Metab; 2020 Apr; 22(4):574-582. PubMed ID: 31797522
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
[No Abstract] [Full Text] [Related]
5. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.
Gallo S; Calle RA; Terra SG; Pong A; Tarasenko L; Raji A
Diabetes Ther; 2020 Aug; 11(8):1849-1860. PubMed ID: 32648108
[TBL] [Abstract][Full Text] [Related]
6. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
Liu J; Pong A; Gallo S; Darekar A; Terra SG
Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
[TBL] [Abstract][Full Text] [Related]
7. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.
Miller S; Krumins T; Zhou H; Huyck S; Johnson J; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Ther; 2018 Feb; 9(1):253-268. PubMed ID: 29313282
[TBL] [Abstract][Full Text] [Related]
8. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
Grunberger G; Camp S; Johnson J; Huyck S; Terra SG; Mancuso JP; Jiang ZW; Golm G; Engel SS; Lauring B
Diabetes Ther; 2018 Feb; 9(1):49-66. PubMed ID: 29159457
[TBL] [Abstract][Full Text] [Related]
9. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
Cherney DZI; Heerspink HJL; Frederich R; Maldonado M; Liu J; Pong A; Xu ZJ; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
Diabetologia; 2020 Jun; 63(6):1128-1140. PubMed ID: 32236732
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies.
Liu J; Tarasenko L; Terra SG; Huyck S; Wu L; Pong A; Calle RA; Gallo S; Darekar A; Mancuso JP
Diab Vasc Dis Res; 2019 Sep; 16(5):415-423. PubMed ID: 31081371
[TBL] [Abstract][Full Text] [Related]
11. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
Pratley R; Dagogo-Jack S; Charbonnel B; Patel S; Hickman A; Liu J; Tarasenko L; Pong A; Ellison MC; Huyck S; Gantz I; Terra SG
Diabetes Obes Metab; 2020 Dec; 22(12):2276-2286. PubMed ID: 32700421
[TBL] [Abstract][Full Text] [Related]
13. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Hollander P; Liu J; Hill J; Johnson J; Jiang ZW; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Ther; 2018 Feb; 9(1):193-207. PubMed ID: 29282633
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
15. The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies.
Gallo S; Raji A; Calle RA; Pong A; Meyer C
Diabetes Obes Metab; 2020 Dec; 22(12):2267-2275. PubMed ID: 32700393
[TBL] [Abstract][Full Text] [Related]
16. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.
Kashiwagi A; Shestakova MV; Ito Y; Noguchi M; Wilpshaar W; Yoshida S; Wilding JPH
Diabetes Ther; 2019 Dec; 10(6):2201-2217. PubMed ID: 31606880
[TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
Kohler S; Zeller C; Iliev H; Kaspers S
Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
Budoff MJ; Davis TME; Palmer AG; Frederich R; Lawrence DE; Liu J; Gantz I; Derosa G
Diabetes Ther; 2021 May; 12(5):1279-1297. PubMed ID: 33721213
[TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
Kohler S; Salsali A; Hantel S; Kaspers S; Woerle HJ; Kim G; Broedl UC
Clin Ther; 2016 Jun; 38(6):1299-1313. PubMed ID: 27085585
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Liu L; Shi FH; Xu H; Wu Y; Gu ZC; Lin HW
Front Pharmacol; 2021; 12():752440. PubMed ID: 35126103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
